Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs

Journal of Drug Delivery Science and Technology

Volumn 21, Issue 1, 2011, Pages 5-16

  Van Hoogevest, P ^a,b   Liu, X ^c   Fahr, A ^c   Leigh, M L S ^a  

^a Phares AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

In vivo dissolution; Liposome formulation intravenous; Liposome formulation oral; Phospholipid formulation intravenous; Phospholipid formulation oral

Indexed keywords

ALPHA TOCOPHEROL; AMPHOTERICIN B LIPID COMPLEX; ASCORBIC ACID PLUS VITAMIN B COMPLEX; ASCORBYL PALMITATE; CHOLESTEROL; CRESOL; CURCUMIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DIAZEPAM; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DOXORUBICIN; EXEMESTANE; FENOFIBRATE; HALOFANTRINE; LIPOFUNDIN; LIPOPROSTAGLANDIN E1; MIFAMURTIDE; NOBILETIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PHYTOMENADIONE; PROGESTERONE; PROPOFOL; RAPAMYCIN; SILYMARIN; UNINDEXED DRUG; VERTEPORFIN; VINPOCETINE;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EMULSION; HUMAN; LIPID VESICLE; LIPOSOMAL DELIVERY; MICELLE; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 79952209766     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(11)50001-2     Document Type: Review

References (135)

1. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. - Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. - Adv. Drug Deliv. Rev., 46, 3-26, 2001.
2. Lennernäs H. - Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a re-evaluation? - Pharm. Res., 12, 1573-1582, 1995. (Pubitemid 26004681)
3. Yu L. X., Amidon G. L., Polli J. E., Zhao H., Mehta M. U., Conner D. P., Shah V. P., Lesko L. J., Chen M. L., Lee V. H.Hussain A. S. - Biopharmaceutics classification system: the scientific basis for biowaiver extensions. - Pharm. Res., 19, 921-925, 2002.
4. FDA U. - Guidance for industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate release oral solid dosage forms based on a biopharmaceutics classification system. - 2000.
5. Porter C. J., Charman W. N. - In vitro assessment of oral lipid based formulations. - Adv. Drug Deliv. Rev., 50, Suppl. 1, S127-147, 2001.
6. Charman W.N., Porter C.J., Mithani S., Dressman J.B. - Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. - J. Pharm. Sci., 86, 269-282, 1997.
7. Butler J. M., Dressman J. B. - The developability classification system: Application of biopharmaceutics concepts to formulation development. - J. Pharm. Sci., in press, 2010.
8. Fahr A., van Hoogevest P., May S., Bergstrand N., ML S. L. - Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. - Eur. J. Pharm. Sci., 26, 251-265, 2005.
9. Fahy E., Subramaniam S., Brown H. A., Glass C. K., Merrill A. H., Jr., Murphy R. C., Raetz C. R., Russell D. W., Seyama Y., Shaw W., Shimizu T., Spener F., van Meer G., VanNieuwenhze M. S., White S. H., Witztum J. L.Dennis E. A. - A comprehensive classification system for lipids. - J. Lipid Res., 46, 839-861, 2005.
10. Tros de llarduya C., Sun Y., Duzgunes N. - Gene delivery by lipoplexes and polyplexes. - Eur. J. Pharm. Sci., 40, 159-170, 2010.
11. Blume A. - A comparative study of the phase transitions of phospholipid bilayers and monolayers. - Biochim. Biophys. Acta, 557, 32-44, 1979.
12. Cullis P. R., de Kruijff B. - Lipid polymorphism and the functional roles of lipids in biological membranes. - Biochim. Biophys. Acta, 559, 399-420, 1979.
13. Israelachvili J. N., Mitchell D. J., Ninham B. W. - Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. - J. Chem. Soc., Faraday Trans., 2, 72, 1525-1568, 1976.
14. Rane S. S., Anderson B. D. - What determines drug solubility in lipid vehicles: is it predictable? - Adv. Drug Deliv. Rev., 60, 638-656, 2008.
15. Leigh S., Leigh M. L. S., Van Hoogevest P. - Direct dissolution. - International Publication No. WO 2006/125591, 30 November 2006.
16. Isele U., Schieweck K., Kessler R., van Hoogevest P., Capraro H. G. - Pharmacokinetics and body distribution of liposomal zinc phthalocyanine in tumor-bearing mice: influence of aggregation state, particle size, and composition. - J. Pharm. Sci., 84, 166-173, 1995.
17. Uran S., Larsen A., Jacobsen P. B., Skotland T. - Analysis of phospholipid species in human blood using normal-phase liquid chromatography coupled with electrospray ionization ion-trap tandem mass spectrometry. - J. Chromatogr. B Biomed. Sci. Appl., 758, 265-275, 2001.
18. Wang C., Xie S., Yang J., Yang Q., Xu G. - Structural identification of human blood phospholipids using liquid chromatography/quadrupole-linear ion trap mass spectrometry. - Analytica Chimica Acta, 525, 1-10, 2004. (Pubitemid 39330380)
19. The AOCS Lipid Library. - http://www.aocs.org.
20. Yoshida M., Kobunai T., Aoyagi K., Saito H., Utsugi T., Wierzba K. Yamada Y. - Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids. - Clin. Cancer Res., 6, 4396-4401, 2000.
21. Kiricuta I. C., Jr., Simplaceanu V. - Tissue water content and nuclear magnetic resonance in normal and tumor tissues. - Cancer Res., 35, 1164-1167, 1975.
22. Gillett M. P., Besterman E. M. - Plasma concentrations of lysollecithin and other phospholipids in the healthy population and in men suffering from atherosclerotic diseases. - Atherosclerosis, 22, 111-124, 1975.
23. Insel P., Ross D., McMahon K. (Eds.) - Nutrition. - Jones & Bartlett, Sudbury, 2010.
24. Bartsch W., Sponer G., Dietmann K., Fuchs G. - Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. - Arzneimittelforschung, 26, 1581-1583, 1976.
25. Parnham M. J., Wetzig H. - Toxicity screening of liposomes. - Chem. Phys. Lipids, 64, 263-274, 1993.
26. Gregoriadis G. (Ed.) - Liposome Technology. - Informa Healthcare, New York, 2007.
27. Teelmann K., Schlappi B., Schupbach M., Kistler A. - Preclinical safety evaluation of intravenously administered mixed micelles. - Arzneimittelforschung, 34, 1517-1523, 1984. (Pubitemid 15203496)
28. Cosmetic Ingredient Review; Final Report on the Safety Assessment of Polysorbates 20, 21, 40, 60, 61, 65, 80, 81 and 85. - J. Am. College Tox., 3, 1-82, 1984.
29. Varma R. K., Kaushal R., Junnarkar A. Y., Thomas G. P., Naidu M. U., Singh P. P., Tripathi R. M.Shridhar D. R. - Polysorbate 80: a pharmacological study. - Arzneimittelforschung, 35, 804-808, 1985.
30. Masini E., Planchenault J., Pezziardi F., Gautier P., Gagnol J. P. - Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. - Agents Actions, 16, 470-477, 1985. (Pubitemid 16220968)
31. Bowers V. D., Locker S., Ames S., Jennings W., Corry R. J. - The hemodynamic effects of Cremophor-EL. - Transplantation, 51, 847-850, 1991.
32. Eschalier A., Lavarenne J., Burtin C., Renoux M., Chapuy E., Rodriguez M. - Study of histamine release induced by acute administration of antitumor agents in dogs. - Cancer Chemother. Pharmacol., 21, 246-250, 1988.
33. Eschalier A., Lavarenne J., Burtin C., Tounissou P. - Acute hemodynamic effects of an antitumoral agent: elliptinium. Involvement of histamine release. - Agents Actions, 17, 441-448, 1986.
34. Ennis M., Lorenz W., Gerland W. - Modulation of histamine release from rat peritoneal mast cells by non-cytotoxic concentrations of the detergents Cremophor El (oxethylated castor oil) and Triton X100. A possible explanation for unexpected adverse drug reactions? - Agents Actions, 18, 235-238, 1986. (Pubitemid 16113264)
35. Ennis M., Lorenz W., Kapp B., Luben L., Schmal A. - Comparison of the histamine-releasing activity of cremophor EL and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. - Agents Actions, 16, 265-268, 1985. (Pubitemid 15116711)
36. Lorenz W., Schmal A., Schult H., Lang S., Ohmann C., Weber D., Kapp B., Luben L.Doenicke A. - Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. - Agents Actions, 12, 64-80, 1982. (Pubitemid 12076385)
37. Lorenz W., Reimann H. J., Schmal A., Dormann P., Schwarz B., Neugebauer E.Doenicke A. - Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. - Agents Actions, 7, 63-67, 1977. (Pubitemid 8070781)
38. Gould S., Scott R. C. - 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. - Food Chem. Toxicol., 43, 1451-1459, 2005.
39. Luke D. R., Tomaszewski K., Damle B., Schlamm H. T. - Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). - J. Pharm. Sci., 99, 3291-3301, 2010.
40. Leigh M. L. S., Van Hoogevest P., Tiemessen H. - Optimising the oral bioavailability of the poorly water soluble drug cyclosporine A using membrane lipid technology. - Drug Delivery Systems & Sciences, 1, 73-77, 2001.
41. FDA U. - Revised 21CFR184.1063.
42. FDA U. - Federal Regulations 21CFR184.1063, 1996.
43. FDA U. - Federal Regulations 21CFR184.1063, 2002.
44. EU. - Commission Directive 96/77/EC, 1996.
45. www.news-medical.net/news/20100107/Phase-II-clinical-trial-results-of- Liposome-Entrapped-Paclitaxel-announced.aspx.
46. van Hoogevest P., Fankhauser P. - An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE). In: Liposomes in the Therapy of Infectious Diseases and Cancer, I.J. Fidler, G. Lopez-Berestein (Eds.), Alan R. Liss Inc., New York, 1989, p. 453.
47. Desai N.R., Agha B.J., Kale K.M. - Liposome compositions of porphyrin photosensitizers. - In: US Patent (Ed.), QLT Phototherapeutics, Inc., Canada, 2000.
48. Strickley R.G. - Solubilizing excipients in oral and injectable formulations. - Pharm. Res., 21, 201-230, 2004.
49. Li P., Zhao L. - Developing early formulations: practice and perspective. - Int. J. Pharm., 341, 1-19, 2007.
50. Janssens S., Van den Mooter G. - Review: physical chemistry of solid dispersions. - J. Pharm. Pharmacol., 61, 1571-1586, 2009.
51. Dhirendra K., Lewis S., Udupa N., Atin K. - Solid dispersions: a review. - Pak. J. Pharm. Sci., 22, 234-246, 2009.
52. Carlson R. P., Hartman D. A., Ochalski S. J., Zimmerman J. L., Glaser K. B. - Sirolimus (rapamycin, Rapamune) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the effects of different oral formulations. - Inflamm. Res., 47, 339-344, 1998.
53. Physician's Desk Reference, Medical Economics Company, Inc., Montvale, NJ, 2003.
54. Fukunaga M., Miller M.M., Deftos L.J. - Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats. - Horm. Metab. Res., 23, 166-167, 1991.
55. Payne N. I., Timmins P., Ambrose C. V., Ward M. D., Ridgway F. - Proliposomes: a novel solution to an old problem. - J. Pharm. Sci., 75, 325-329, 1986.
56. Leigh S. - Liposome-forming composition. - European Patent EP 0158 441 B2, 16 October 1985.
57. Yan-yu X., Yun-mei S., Zhi-peng C., Qi-neng P. - Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. - Int. J. Pharm., 319, 162-168, 2006.
58. Xu H., He L., Nie S., Guan J., Zhang X., Yang X.Pan W. - Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. - J. Control. Release, 140, 61-68, 2009.
59. Lin W., Yao J., Zhou J. P. - [Preparation of self-assemble nobiletin proliposomes and its pharmacokinetics in rats]. - Yao Xue Xue Bao, 44, 192-196, 2009.
60. Takahashi M., Uechi S., Takara K., Asikin Y., Wada K. - Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. - J. Agric. Food Chem., 57, 9141-9146, 2009.
61. Hiremath P. S., Soppimath K. S., Betageri G. V. - Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. - Int. J. Pharm., 380, 96-104, 2009.
62. Chen Y., Lu Y., Chen J., Lai J., Sun J., Hu F.Wu W. - Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. - Int. J. Pharm., 376, 153-160, 2009.
63. Shah N. M., Parikh J., Namdeo A., Subramanian N., Bhowmick S. - Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. - J. Nanosci. Nanotechnol., 6, 2967-2973, 2006.
64. Potluri P., Betageri G. V. - Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. - Drug Deliv., 13, 227-232, 2006.
65. Brocks D. R., Betageri G. V. - Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation. - J. Pharm. Pharmacol., 54, 1049-1053, 2002.
66. Stozek T., Borysiewicz J. - [Bioavailability of griseofulvin in the form of liposomes]. - Pharmazie, 46, 39-41, 1991.
67. Stozek T. - [Effect of dipyridamole in liposomes on its rectal absorption]. - Acta Pol. Pharm., 44, 206-211, 1987.
68. Stozek T., Krowczynski L. - [The bioavailability of dipyridamole in the form of liposomes]. - Pharmazie, 41, 645-647, 1986.
69. Stozek T. - Bioavailability of indomethacin in liposomes. - Acta Pol. Pharm., 49, 21-26, 1992.
70. El-Samaligy M. S., Afifi N. N., Mahmoud E. A. - Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. - Int. J. Pharm., 308, 140-148, 2006.
71. Maurer B.J., Kalous O., Yesair D.W., Wu X., Janeba J., Maldonado V., Khankaldyyan V., Frgala T., Sun B. C., McKee R. T., Burgess S. W., Shaw W. A.Reynolds C. P. - Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. - Clin. Cancer Res., 13, 3079-3086, 2007.
72. Leigh M. L. S., Van Hoogevest, P., Tiemessen, H. - Optimising the bioavailability of the poorly water soluble drug cyclosporine A using membrane lipid technology. - Drug Delivery Systems & Sciences, 1, 73-77, 2001.
73. Pouton C. W. - Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. - Eur. J. Pharm. Sci., 29, 278-287, 2006.
74. Müllertz A., Ogbonna A., Ren S., Rades T. - New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. - J. Pharm. Pharmacol., in press, 2010.
75. Persson E. M., Gustafsson A. S., Carlsson A. S., Nilsson R. G., Knutson L., Forsell P., Hanisch G., Lennernas H.Abrahamsson B. - The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. - Pharm. Res., 22, 2141-2151, 2005.
76. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J. B. - Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. - Pharm. Res., 15, 698-705, 1998.
77. Dressman J. B., Thelen K., Jantratid E. - Towards quantitative prediction of oral drug absorption. - Clin. Pharmacokinet., 47, 655-667, 2008.
78. Dressman J. B., Vertzoni M., Goumas K., Reppas C. - Estimating drug solubility in the gastrointestinal tract. - Adv. Drug Deliv. Rev., 59, 591-602, 2007.
79. Vogt M., Kunath K., Dressman J. B. - Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. - Eur. J. Pharm. Biopharm., 68, 330-337, 2008.
80. Kuentz M. - Drug absorption modeling as a tool to define the strategy in clinical formulation development. - AAPS J., 10, 473-479, 2008.
81. Schwebel H. J., van Hoogevest P., Leigh M. L., Kuentz M. - The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs. - Pharm. Dev. Technol., 2010.
82. Jantratid E., Janssen N., Reppas C., Dressman J. B. - Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. - Pharm. Res., 25, 1663-1676, 2008.
83. Dahan A., Hoffman A. - Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. - J. Control. Release, 129, 1-10, 2008.
84. Dahan A., Hoffman A. - The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. - Eur. J. Pharm. Biopharm., 67, 96-105, 2007.
85. Marques M. - Dissolution media simulating fasted and fed states. - DissolutionTechnologies, 11, 16, 2004.
86. Friberg S.E.(Ed.) - Organized Solutions: Surfactants in Science and Technology (Optical Engineering). - Marcel Dekker Inc., 1992.
87. Johnson K.C., Swindell A.C. - Guidance in the setting of drug particle size specification to minimize variability in absorption. - Pharm. Res., 13, 1996.
88. Kerns E. H., Di L. (Eds.) - Drug like properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization. - Academic Press/Elsevier Inc., Burlington, San Diego, London, 2008.
89. Hilfiker R., Blatter F., von Raumer M. - Relevance of solid state properties for pharmaceutical products. - In: Polymorphism in Pharmaceutical Industry, R. Hilfiker Ed., Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim, 2006.
90. Gao P., Morozowich W. - Development of supersaturated self emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. - Expert Opin. Drug Deliv., 3, 97-110, 2006.
91. Kloefer B., Van Hoogevest, P., Moloney, R., Kuentz, M., Leigh, M.L.S, Dressman, J. - Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF. - Dissolution Technologies, 17, 6-13, 2010.
92. Collins-Gold L.C., Lyons R.T., Bartholow L.C. - Parenteral emulsions for drug delivery. - Adv. Drug Deliv. Rev., 5, 189-208, 1990.
93. Gupta P.K., Cannon J.B. - Emulsions and microemulsions for drug solubilization and delivery. - In: Water-Insolube Drug Formulation, R. Liu Ed., Interpharm/CRC, Boca Raton, London, New York, Washington, D.C., 2000, pp. 169-212.
94. Sila-on W., Vardhanabhuti N., Ongpipattanakul B., Kulvanich P. - Influence of incorporation methods on partitioning behavior of lipophilic drugs into various phases of a parenteral lipid emulsion. - AAPS PharmSciTech, 9, 684-692, 2008.
95. Maia A. M., Baby A. R., Pinto C. A., Yasaka W. J., Suenaga E., Kaneko T. M.Velasco M. V. - Influence of sodium metabisulfite and glutathione on the stability of vitamin C in o/w emulsion and extemporaneous aqueous gel. - Int. J. Pharm., 322, 130-135, 2006.
96. Strickley R.G., Anderson B.D. - Solubilization and stabilization of an anti-HIV thiocarbamate, NSC 629243, for parenteral delivery, using extemporaneous emulsions. - Pharm. Res., 10, 1076-1082, 1993.
97. Prankerd R.J., Stella V.J. - The use of oil-in-water emulsions as a vehicle for parenteral drug administration. - J. Parenter. Sci. Technol., 44, 139-149, 1990.
98. Gahwiller C., von Planta C., Schmidt D., Steffen H. - [Size, structure, and dynamics of bile salt/lecithin mixed micelles (author's transl)]. - Z. Naturforsch. C, 32, 748-755, 1977. (Pubitemid 8198845)
99. Supersaxo A., Hein W.R., Steffen H. - Mixed micelles as a proliposomal, lymphotropic drug carrier. - Pharm. Res., 8, 1286-1291, 1991.
100. Forrest P., Galletly D. C. - A double-blind comparative study of three formulations of diazepam in volunteers. - Anaesth. Intensive Care, 16, 158-163, 1988.
101. Guentert T.W., Oie S., Paalzow L., Frey B.M., Brandt R., Aarons L.J., Rowland M. - Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs. - Br. J. Clin. Pharmacol., 23, 569-577, 1987.
102. Galletly D.C., Wilson L.F., Treuren B.C., Boon B.P. - Diazepam mixed micelle, Comparison with diazepam in propylene glycol and midazolam. - Anaesth. Intensive Care, 13, 352-354, 1985.
103. Bangham A.D. - Surrogate cells orTrojan horses. The discovery of liposomes. - Bioessays, 17, 1081-1088, 1995.
104. Forssen E.A. - The design and development of DaunoXome for solid tumor targeting in vivo. - Adv. Drug Del. Rev., 24, 133-150, 1997.
105. Gabizon A., Shmeeda H., Barenholz Y. - Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. - Clinical Pharmacokinetics, 42, 419-436, 2003. (Pubitemid 36649037)
106. Leonard R.C., Williams S., Tulpule A., Levine A.M., Oliveros S. - Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). - Breast, 18, 218-224, 2009.
107. Gulati M., Bajad S., Singh S., Ferdous A.J., Singh M. - Development of liposomal amphotericin B formulation. - J. Microencapsul., 15, 137-151, 1998.
108. Braun D. G., van Hoogevest P., Schumann G. - In: Adjuvants: Theory and Practical Applications: Muramyltripeptide-Phosphatidylethanolamine MTP-PE - A Muramyldipeptide Derivative with Lipophilic Properties, D.E.S. Stewart-Tull Ed., Butterworth-Heinemann, Oxford, 1994.
109. Schumann G., van Hoogevest P., Fankhauser P., Probst A., Peil A., Court M., Schaffner J.C., Fischer M., Skripsky T., Graepel P. - Comparison of free and liposomal MTP-PE: pharmacological and toxicological aspects. - In: Liposomes in the Therapy of Infectious Diseases and Cancer, I.J. Fidler, G. Lopez-Berestein Eds., Alan R. Liss Inc., New York, 1989, p. 191.
110. Veerareddy P.R., Vobalaboina V. - Lipid-based formulations of amphotericin B. - Drugs Today (Barc.), 40, 133-145, 2004.
111. Chowdhary R.K., Sharif I., Chansarkar N., Dolphin D., Ratkay L., Delaney S.H.M. - Correlation of photosensitizer delivery to lipoproteins and efficacy in tumor and arthritis mouse models; comparison of lipid-based and Pluronic P123 formulations. - Pharm. Pharmaceut. Sci., 6, 198-204, 2003.
112. Li P., Zhao L. - Developing early formulations: practice and perspective. - Int. J. Pharm., 314, 1-19, 2007.
113. Van Hoogevest P., Rogue V., Brumec M., Schwebel H., Grunkemeyer J.L., Leigh M.L. - Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration. - PDA J. Pharm. Sci. Technol., 60, 366-377, 2006.
114. Bittner B., Mountfield R. J. - Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. - Curr. Opin. Drug Discov. Devel., 5, 59-71, 2002.
115. Tall A. R., Tabas I., Williams K. J. - Lipoprotein-liposome interactions. - Methods Enzymol., 128, 647-657, 1986.
116. van Berkel T.J., van Tol A. - In vivo uptake of human and rat low density and high density lipoprotein by parenchymal and nonparenchymal cells from rat liver. - Biochim. Biophys. Acta, 530, 299-304, 1978.
117. Van Berkel T.J., Koster J.F., Hulsmann W.C. - High density lipoprotein and low density lipoprotein catabolism by human liver and parenchymal and non-parenchymal cells from rat liver. - Biochim. Biophys. Acta, 486, 586-589, 1977.
118. Madorin M., van Hoogevest P., Hilfiker R., Leuenberger H. - The use of fluorescence resonance energy transfer to study the disintegration kinetics of liposomes containing lysolecithin and oleic acid in rat plasma. - Pharm. Res., 17, 1118-1123, 2000.
119. Scherphof G., Morselt H. - On the size-dependent disintegration of small unilamellar phosphatidylcholine vesicles in rat plasma. Evidence of complete loss of vesicle structure. - Biochem. J., 221, 423-429, 1984.
120. Scherphof G., Morselt H., Regts J., Wilschut J.C. - The involvement of the lipid phase transition in the plasma-induced dissolution of multilamellar phosphatidylcholine vesicles. - Biochim. Biophys. Acta, 556, 196-207, 1979.
121. Scherphof G., Roerdink F., Waite M., Parks J. - Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. - Biochim. Biophys. Acta, 542, 296-307, 1978.
122. Zborowski J., Roerdink F., Scherphof G. - Leakage of sucrose from phosphatidylcholine liposomes induced by interaction with serum albumin. - Biochim. Biophys. Acta, 497, 183-191, 1977.
123. Tall A. R., Krumholz S., Olivecrona T., Deckelbaum R. J. - Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. - J. Lipid Res., 26, 842-851, 1985.
124. Tall A. R., Blum C. B., Grundy S. M. - Incorporation of radioactive phospholipid into subclasses of high-density lipoproteins. - Am. J. Physiol., 244, E513-516, 1983.
125. Tall A.R., Forester L.R., Bongiovanni G.L. - Facilitation of phosphatidylcholine transfer into high density lipoproteins by an apolipoprotein in the density 1.20-1.26 g/ml fraction of plasma. - J. Lipid Res., 24, 277-289, 1983.
126. Tall A.R., Green P.H. - Incorporation of phosphatidylcholine into spherical and discoidal lipoproteins during incubation of egg phosphatidylcholine vesicles with isolated high density lipoproteins or with plasma. - J. Biol. Chem., 256, 2035-2044, 1981.
127. Tall A. R. - Studies on the transfer of phosphatidylcholine from unilamellar vesicles into plasma high density lipoproteins in the rat. - J. Lipid Res., 21, 354-363, 1980.
128. Guo L.S., Hamilton R.L., Goerke J., Weinstein J.N., Havel R.J. - Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. - J. Lipid Res., 21, 993-1003, 1980.
129. Fahr A., van Hoogevest P., Kuntsche J., Leigh M.L. - Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? - J. Liposome Res., 16, 281-301, 2006. (Pubitemid 44359001)
130. Fahr A., Liu X. - Utilization of liposomes for studying drug transfer and uptake. - Methods Mol. Biol., 606, 1-10, 2010.
131. Fahr A., Reiter G. - Biophysical characterization of liposomal delivery systems for lipophilic drugs: cyclosporin A as an example. - Cellular & Molecular Biology Letters, 4, 611-623, 1999. (Pubitemid 30016986)
132. Fahr A., Nimmerfall F., Wenger R. - Interactions of cyclosporine and some derivatives with model membranes: Binding and ion permeability changes. - Transplantation Proceedings, 26, 2837-2841, 1994. (Pubitemid 24329335)
133. Fahr A., Holz M., Fricker G. - Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics. - Pharm. Res., 12, 1189-1198, 1995.
134. Petersen S., Fahr A., Bunjes H. - Flow cytometry as a new approach to investigate drug transfer between lipid particles. - Mol. Pharm., 7, 350-363, 2010.
135. Fetterly G. J., Straubinger R. M. - Pharmacokinetics of paclitaxel-containing liposomes in rats. - AAPS PharmSci, 5, E32, 2003.